Gedeon Richter PLC (0QFP)
London Exchange · UK · prices in GBP · close of 20 Oct 2026
Key indicators
| Last close | GBP 5,040.00 |
|---|---|
| 52-week range | 5,033.45 – 13,212.79 |
| Return, 1 month / 3 months | +0.0% / +0.0% |
| Return, 1 year / 3 years | +0.1% / +0.3% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 100 |
| Volatility (1 year) | 0.1% |
| Worst drawdown (1 year) | 0.0% |
| Average daily value traded | 9.67M GBP |
| Dividend yield | 0.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Gedeon Richter is a pharmaceutical company based in Budapest, Hungary. It develops, manufactures and markets branded and generic medicines, with particular strength in women's health and treatments for conditions of the central nervous system. The company also produces active pharmaceutical ingredients and operates through a network of subsidiaries that supply hospitals, pharmacies and healthcare providers in Europe and other markets around the world.
The shares are listed on the London Exchange in UK under the code 0QFP, and the price on this page is in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Gedeon Richter PLC (0QFP) trades on the London Exchange in UK. It last closed at GBP 5,040.00 on 20 October 2026.
Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 939 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 0.1% and over the last three months it rose 0.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 64 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 0.1% | ||
| From 52-week high | 0.0% | ||
| Momentum | 49 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 0.0% | ||
| 6-month return | 0.1% | ||
| 12-month return, skipping the last month | 0.1% | ||
| Stability (higher is calmer) | 99 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 0.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | 0.0% | ||
| Liquidity | 51 · Fair | Moderate trading activity. | |
| Average daily value traded | 9.67M GBP | ||
| Zero-volume days | 81.7% | ||
| Income | 38 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.1% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +0.0% |
| 3 months | +0.0% |
| 6 months | +0.1% |
| 1 year | +0.1% |
| 3 years | +0.3% |
| 5 years | +0.4% |
Signals
| 50-day / 200-day average | 5,040.00 / 5,036.69 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2,952.32 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Jun 2026 | GBX 6.5546 |
| 3 Jun 2025 | GBX 5.0856 |
| 5 Jun 2024 | GBX 4.3198 |
| 7 Jun 2023 | GBX 3.9000 |
| 8 Jun 2022 | GBX 2.2517 |
| 4 Jun 2021 | GBX 2.2532 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.